Clinical Trials Logo

Clinical Trial Summary

Melasma (also called chloasma and pregnancy mask) is characterized by pigmented lesions darker than their usual complexion on the faces of affected subjects.

The physiopathology of melasma is still poorly understood. To date, the factors that favor the onset of melasma appear to be: genetic predisposing factors, changes in sex hormone levels, and sun exposure.

Vascularization as well as elastosis also appear to be increased in skin with melasma.

The aim of this study is to evaluate the different levels of expression of biomarkers between pigmented melasma lesions and surrounding healthy skin when melasma is highly pigmented but also when it is dormant (ie treated melasma, without UV solicitation in the heart of winter). The goal is to identify and better understand the involvement of different genes and proteins and thus offer more specific ways of care, and therefore effective, for the subjects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03618277
Study type Interventional
Source Pierre Fabre Dermo Cosmetique
Contact
Status Withdrawn
Phase N/A
Start date October 10, 2018
Completion date October 10, 2018

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03585179 - Oral and Topical Tranexamic Acid for the Treatment of Melasma Phase 3
Recruiting NCT06418568 - Efficacy and Safety Trial of Using Ultra-Pulsed Shockwaves to Deliver Tranexamic Acid for the Treatment of Melasma N/A